The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial.
 
Patrizia Giannatempo
No Relationships to Disclose
 
Andrea Franza
No Relationships to Disclose
 
Laura Marandino
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Alessandra Alessi
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Liana Bevilacqua
No Relationships to Disclose
 
Giusy Russo
No Relationships to Disclose
 
Marzia Del Re
Consulting or Advisory Role - Celgene; Ipsen; Janssen-Cilag; Roche Molecular Diagnostics; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ipsen; Janssen-Cilag; Novartis; Pfizer; Sanofi
 
Andrea Anichini
No Relationships to Disclose
 
Francesco Sgambelluri
No Relationships to Disclose
 
Pierangela Sepe
No Relationships to Disclose
 
Matteo Zimatore
No Relationships to Disclose
 
Melanie Claps
No Relationships to Disclose
 
Elena Verzoni
No Relationships to Disclose
 
Valentina Guadalupi
No Relationships to Disclose
 
Arianna Ottini
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb (BMS); Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)